Antiretroviral therapy (ART) initiated in the acute phase of HIV infection (AHI) results in a smaller viral reservoir. However, the impact of early HIV-specific T-cell responses on long-term reservoir ...

NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune ...

NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune ...

First gamma-delta (γδ) TCE to demonstrate significant γδ T cell expansion and activation, potentially offering an alternative to conventional CD3-based approaches without significant adverse ...

IN8bio Unveils Promising New Data from Next Generation Gamma-Delta T Cell Engager (TCE ... changes in dangerous cytokines, such as IL-6, IL-10, and IL-17a – markers that are often linked to ...

(RTTNews) - IN8bio, Inc. (INAB) announced the launch of its next-generation Gamma-Delta T-cell engager or TCE platform INB-600, designed to overcome the limitations of existing Gamma-Delta TCE ...

Proprietary platform represents the first known approach capable of sustained gamma-delta T cell expansion, eliminating target cells with robust potency INB-619, a next generation gamma-delta TCE ...

Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company's lead program, ...